BLA for Narsoplimab in HSCT-TMA Accepted for Priority Review
Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
-- FDA sets PDUFA date of July 17, 2021 --
-- FDA sets PDUFA date of July 17, 2021 --
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.